Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
P/E ratio for Oncolytics Biotech Inc. (ONCY)
P/E ratio as of 2023: -4.26
According to Oncolytics Biotech Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.26. At the end of 2022 the company had a P/E ratio of -5.16.
P/E ratio history for Oncolytics Biotech Inc. from 1999 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -4.26 |
| 2022 | -5.16 |
| 2021 | -3.57 |
| 2020 | -6.26 |
| 2019 | -3.00 |
| 2018 | -2.32 |
| 2017 | -5.97 |
| 2016 | -2.24 |
| 2015 | -3.07 |
| 2014 | -2.91 |
| 2013 | -5.85 |
| 2012 | -8.16 |
| 2011 | -9.72 |
| 2010 | -20.85 |
| 2009 | -7.93 |
| 2008 | -3.48 |
| 2007 | -4.40 |
| 2006 | -6.18 |
| 2005 | -13.86 |
| 2004 | -12.18 |
| 2003 | -12.13 |
| 2002 | -6.41 |
| 2001 | -20.06 |
| 2000 | -35.07 |
| 1999 | -76.01 |